BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bavarian Nordic (DK:BAVA) Invests USD 40 Million In Production Facility


10/19/2005 5:09:21 PM

COPENHAGEN, Denmark, Dec. 2 /PRNewswire/ -- Bavarian Nordic acquires a pharmaceutical production facility and establishes its own production of vaccines. The facility will be one of Europe's largest production sites for vaccines with the capacity to produce up to 120 million doses per year.

Bavarian Nordic has entered into an agreement with Orion Pharma to acquire the Finnish pharmaceutical company's production facility and administrative offices located in Kvist-gaard, Denmark 30 kilometres north of Copenhagen.

The total investment will be approximately USD 40 million. The site will be re-designed for vaccine production with a capacity to produce up to 120 million doses per year, thus making Bavarian Nordic one of the largest vaccine producers in Europe. The purchase price for Orion Pharma's facility will be covered by the company's existing liquidity, combined with its own income and bank financing.

Peter Wulff, CEO and President commented, "This acquisition is an important milestone in Bavarian Nordic's transformation from a biotech company to a biopharmaceutical company. The new site ensures that we can meet the growing international demand for our safe MVA vaccines against HIV, tropical diseases and smallpox. As the leader in setting new standards for development and production of vaccines, this acquisition strengthens our global leadership position within MVA vaccines."

"Over the last year, we have evaluated several international options in the USA, Canada, Germany, France and Sweden. However the site in Kvistgaard offers significant advantages as it is relatively new, is perfect in terms of size and design and offers unique conditions in relation to our need for a qualified workforce," said Wulff.

Bavarian Nordic currently has facilities in Munich, Berlin and Copenhagen. The company will move its headquarters and administrative functions to Kvistgaard while the clinical trial materials facility will remain in Berlin. The company also has plans over the next year to significantly strengthen its research organisation in Munich.

The new vaccine facility will be ready for manufacture in 2005 and initially will produce vaccines against smallpox for the US and European markets along with various planned vaccines against HIV.

The company's production partnership with the German vaccine manufacturer IDT will continue and be expanded due to the expected increase demand for vaccines against smallpox and HIV in the coming years.

About Bavarian Nordic:

Founded in 1994, Bavarian Nordic A/S is a leading biopharmaceutical company in the field of innovative vaccines to prevent and treat infectious diseases. With operations in Denmark and Germany, Bavarian Nordic employs 90 people and is listed on the Copenhagen Stock Exchange under the trading symbol BAVA.

Bavarian Nordic's proprietary core technology MVA-BN, is one of the world's safest, multivalent vaccine vectors and ideally suited for use against various infectious diseases such as smallpox, HIV, Japanese Encephalitis and Dengue Fever. Several MVA-BN-based HIV and smallpox vaccines are in clinical Phase I and Phase II trials.

With respect to smallpox vaccines, Bavarian Nordic has supply and development contracts with the governments of Germany, U.K. and U.S.A., among other countries. One of the company's development agreements includes a three-year contract (awarded in February 2003) with the U.S. Department of Health and Human Services to develop MVA-BN as a safe third-generation smallpox vaccine.

Bavarian Nordic's partners include Chiron and Epimmune of the U.S.A., Gerolymatos of Greece, Impfstoffwerk Dessau-Tornau (IDT) of Germany, and Vaccine Solutions of Australia.

For more information please visit http://www.bavarian-nordic.com/

Bavarian Nordic

CONTACT: Peter Wulff, President & CEO, or Elizabeth Dempsey Becker,Director of Communications, both of Bavarian Nordic, +45-33-26-83-83; orUnited Kingdom, Paula Crymble or Mary Clark, both of Capital MSL,+44-20-7878-3181; or United States, Kristen Neese, +1-212-468-3914, or FeliciaMorton, +1-212-468-4250, both of Manning, Salvage and Lee, all for BavarianNordic



Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES